-+ 0.00%
-+ 0.00%
-+ 0.00%

Gilead completes Arcellx acquisition at USD 115 per share plus CVR

PUBT·04/28/2026 12:45:49
Listen to the news
Gilead completes Arcellx acquisition at USD 115 per share plus CVR
  • Gilead completed its acquisition of Arcellx at USD 115 per share in cash.
  • Deal terms include a non-transferable contingent value right of USD 5 per share.
  • Transaction implied equity value was about USD 7.8 billion at closing.
  • CVR pays out if cumulative global net sales of anito-cel reach at least USD 6 billion from launch through end-2029.
  • Arcellx became a wholly owned Gilead subsidiary, delisting its shares from Nasdaq.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gilead Sciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260427408690) on April 28, 2026, and is solely responsible for the information contained therein.